Beijing, Sept 4, 2026 — China’s Center for Drug Evaluation (CDE) proposed adding GH56 capsules, developed by Genhouse Biosciences (Suzhou) Co., Ltd., to the Starlight Program pilot for encouraging pediatric antitumor drug development, targeting MTAP-deficient bone and soft tissue tumors in children with a public comment deadline of Sept 11, 2026.

Program Snapshot

Attribute	Detail
Program	Starlight Program (Pediatric Antitumor Drug Development Incentive Pilot)
Product	GH56 Capsules
Applicant	Genhouse Biosciences (Suzhou) Co., Ltd.
Indication	MTAP-deficient bone and soft tissue tumors (pediatric)
Comment deadline	Sept 11, 2026
Contact	etdrugs@cde.org.cn

Clinical Context

MTAP (methylthioadenosine phosphorylase) deficiency is a metabolic vulnerability found in a subset of bone and soft tissue tumors, including certain sarcomas. The enzyme deficiency creates a dependency on alternative metabolic pathways, making it an attractive target for precision oncology approaches. Pediatric bone and soft tissue sarcomas represent a high-unmet-need area with limited targeted therapeutic options, particularly for relapsed or refractory cases.

Market Impact Analysis

The inclusion of GH56 in the Starlight Program signals CDE’s commitment to expanding China’s pediatric oncology pipeline beyond traditional cytotoxic chemotherapy into molecularly targeted therapies. Genhouse Biosciences, a Suzhou-based biotech firm, is leveraging the metabolic dependency created by MTAP deletion—a niche but biologically compelling target that has gained traction in global oncology research.

For the pediatric cancer drug landscape, the Starlight Program provides a regulatory fast lane that may include expedited clinical trial consultations, rolling data submissions, and priority review pathways. The one-week comment window—shorter than typical CDE public consultations—suggests regulators view the application as aligned with the pilot’s urgent mandate to address life-threatening pediatric malignancies with few existing options.

The MTAP-deficient indication is particularly noteworthy because it represents a biomarker-driven approach in a pediatric population, where precision medicine adoption has historically lagged adult oncology due to smaller trial populations and limited commercial incentives. By backing GH56, regulators are validating the biomarker strategy for pediatric solid tumors and potentially encouraging additional submissions targeting metabolic vulnerabilities in childhood cancers.

Forward-Looking Statement

Industry analysts expect GH56 to advance into pediatric clinical trials under the Starlight Program’s enhanced regulatory support framework, with Phase I/II studies potentially initiating by early 2027 if preclinical pediatric data packages are complete. Success in MTAP-deficient bone and soft tissue tumors could establish a proof-of-concept for metabolic targeting in pediatric sarcomas, opening pathways for broader development in other MTAP-null malignancies such as certain gliomas or lymphomas. The pilot’s backing also reinforces China’s strategic push to build domestic pediatric oncology capabilities, reducing reliance on imported therapies for rare childhood cancers. Final pilot inclusion is anticipated following the Sept 11 comment deadline, barring substantive objections.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/9983d299d8178d5ef071ceb4dd33e276

Beijing, Sept 1, 2026 — China’s Center for Drug Evaluation (CDE) issued two technical guidelines for chemical generic drug eye drops, establishing research and development standards for standard and specialized ophthalmic formulations as regulators expand quality consistency evaluations beyond oral solids and injections.

Policy Snapshot

Attribute	Detail
Issuer	Center for Drug Evaluation (CDE), National Medical Products Administration
Document	Technical Guidelines for Research on Chemical Generic Drug Eye Drops; Technical Guidelines for Research on Chemical Generic Drug Special Eye Drops
Announcement No.	2026 No. 43
Legal basis	State Council General Office Opinion on Deepening Drug and Medical Device Regulatory Reform (Guo Ban Fa [2024] No. 53)
Effective date	Sept 1, 2026
Scope	Chemical generic drug eye drops (standard and specialized formulations)

Key Provisions

The CDE released two complementary guidelines:

• Standard eye drops — The Technical Guidelines for Research on Chemical Generic Drug Eye Drops outlines requirements for formulation development, quality control, and bioequivalence assessment for conventional ophthalmic solutions and suspensions.
• Specialized eye drops — The Technical Guidelines for Research on Chemical Generic Drug Special Eye Drops addresses complex formulations including emulsions, gels, and sustained-release ophthalmic preparations, setting higher evidentiary bars for therapeutic equivalence.

Both documents align with the NMPA’s broader consistency evaluation framework and require marketing authorization holders to conduct comprehensive quality and efficacy studies referencing approved originator products.

Market Impact Analysis

The guidelines operationalize the NMPA’s Aug 2026 announcement expanding consistency evaluation to eye drops, giving manufacturers immediate technical direction for reformulation and registration. For domestic ophthalmic generics makers, the standards clarify previously ambiguous requirements around in vitro release testing, container closure integrity, and ocular tolerability studies—areas where Chinese generics have historically lagged global benchmarks.

The specialized eye drops guideline is particularly significant for complex formulations such as cyclosporine emulsions and prostaglandin analog suspensions, where therapeutic equivalence cannot be established through simple physicochemical matching. By mandating additional clinical endpoint or pharmacokinetic studies for these categories, regulators are raising the innovation threshold and potentially culling low-quality copycats from the market.

Multinational originator companies with leading ophthalmic franchises may benefit from prolonged market exclusivity as domestic generics face steeper development hurdles, though the guidelines also provide a clearer pathway for high-quality local entrants to compete on clinical evidence.

Forward-Looking Statement

Industry analysts expect the guidelines to trigger a wave of supplemental applications and new generic filings for eye drops in the fourth quarter of 2026, as manufacturers race to establish consistency evaluation portfolios ahead of anticipated delisting deadlines for non-compliant products. The CDE is likely to publish a dedicated reference preparations catalog for ophthalmic generics by year-end, enabling holders to select comparator products for equivalence studies. Companies with existing eye drop portfolios should audit their formulations against the new guidelines immediately, as the specialized eye drops provisions may require costly formulation redevelopment or additional clinical trials. The standards are expected to elevate overall quality in China’s ophthalmic generics sector, potentially opening export opportunities to regulated markets that recognize Chinese consistency evaluation data.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/86f260be2272ece3d89e6dda2eaea22e

Beijing — China’s National Medical Products Administration (NMPA) expanded its generic drug quality and efficacy consistency evaluation program beyond oral solid dosage forms and injections, adding eye drops, transdermal patches, and sprays to the reform framework as Beijing deepens its push to upgrade the domestic pharmaceutical sector.

Policy Snapshot

Attribute	Detail
Issuer	National Medical Products Administration (NMPA)
Announcement	2026 No. 86
Legal basis	State Council General Office Opinion on Deepening Drug and Medical Device Regulatory Reform (Guo Ban Fa [2024] No. 53)
Scope	Chemical generic drugs in non-oral, non-injectable dosage forms
Initial phase	Eye drops — effective immediately upon announcement
Second phase	Patches and sprays — effective July 1, 2027
Reference standard	NMPA Chemical Generic Drug Reference Preparations Catalog

Key Provisions

• Expanded coverage — The consistency evaluation regime, previously focused on oral solids and injections, now extends to eye drops, transdermal patches, and sprays. Marketing authorization holders must select reference preparations from the NMPA-published catalog and submit consistency evaluation applications.
• Technical alignment — Supplemental applications for consistency evaluation must meet the same technical standards as new chemical generic drug applications. Holders should conduct studies according to NMPA technical guidelines and Chinese Pharmacopoeia standards, with the option to reference foreign regulatory requirements. Application summaries follow the 2020 No. 2 CDE notice on injection consistency evaluations; other sections follow the current M4 CTD format.
• Clinical trial gate — Products requiring clinical studies must first obtain clinical trial permits from the CDE before initiating studies.
• Review process — The CDE conducts technical reviews, initiates verification inspections and testing, and issues comprehensive evaluation opinions. Approved products receive supplemental application approval certificates.
• Transitional rules — Unaddressed matters continue to follow the 2017 No. 100 and 2018 No. 102 announcements on consistency evaluation.

Market Impact Analysis

The phased rollout gives eye drop manufacturers immediate compliance obligations while granting patch and spray developers a roughly 10-month runway to prepare dossiers. The extension represents the final frontier of China’s decade-long generic drug quality overhaul, targeting dosage forms that have historically escaped bioequivalence scrutiny due to complex absorption profiles and limited reference standards.

For ophthalmic generics makers, the immediate launch means existing products face potential delisting if they fail to demonstrate therapeutic equivalence to reference preparations within forthcoming deadlines. The sector is fragmented among dozens of domestic producers of glaucoma, anti-inflammatory, and artificial tear formulations, suggesting consolidation pressure as smaller firms lack the R&D budgets to reformulate or conduct clinical endpoint studies.

Patch and spray manufacturers benefit from the delayed July 2027 start date but must begin reference preparation selection and formulation development now to meet what will likely be stringent pharmacokinetic or clinical efficacy requirements. The explicit permission to reference foreign regulatory standards offers a compliance shortcut for multinational subsidiaries with existing EU or U.S. approval packages, though all submissions must ultimately conform to the M4 CTD structure.

Forward-Looking Statement

Industry analysts expect the CDE to publish dedicated technical guidelines for eye drop consistency evaluation by late 2026 or early 2027, clarifying whether in vitro dissolution or clinical efficacy trials will serve as the primary equivalence benchmark. The patch and spray delay to July 2027 suggests regulators recognize the technical complexity of transdermal and pulmonary delivery systems and may use the interim period to develop specialized bioequivalence protocols. Pharmaceutical companies with portfolios spanning these dosage forms should prioritize reference preparation selection and pre-formulation studies immediately, as the supplemental application queue is likely to swell once all three categories are active. The reform aligns with Beijing’s broader industrial policy to elevate domestic generics toward global quality parity, potentially paving the way for increased export competitiveness in regulated markets.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260902093151132.html